Acetylsalicylic Acid

證據等級: L5

預測適應症: 9 個

Note up front: I'm treating predicted_indications[0] (rank 1: "migraine with brainstem aura") as the primary predicted indication per the template's extraction rules, since that's the array's first entry. The evidence pack also contains 8 additional candidate indications (including a much stronger thrombotic disease signal at L1/S3) that fall outside this template's single-indication scope — flagging that here in case a follow-up report on that candidate is wanted.

Acetylsalicylic Acid: From Pain, Fever, and Inflammation to Migraine with Brainstem Aura

One-Sentence Summary

Acetylsalicylic acid (aspirin) is a long-established analgesic, antipyretic, anti-inflammatory, and antiplatelet agent, though its specific original indication is not documented in the current regulatory dataset. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, a rare migraine subtype, with 0 dedicated clinical trials but 19 supporting publications, most of which address migraine or migraine-with-aura broadly rather than this specific subtype.

Quick Overview

Item	Content
Original Indication	Not documented in the Norway regulatory dataset (no license records on file); generically known as an analgesic, antipyretic, anti-inflammatory, and antiplatelet agent
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.94%
Evidence Level	L3
Norway Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for acetylsalicylic acid is not available in the current DrugBank extract (flagged in this evidence pack as a High-severity data gap). Based on well-established pharmacology, however, aspirin irreversibly inhibits cyclooxygenase (COX-1/COX-2), blocking prostaglandin and thromboxane A2 synthesis. This reduces platelet aggregation and dampens prostaglandin-mediated neurogenic inflammation and vascular dilation — mechanisms implicated in migraine pathophysiology.

Migraine with aura, including the rarer brainstem-aura subtype, is driven substantially by cortical spreading depression and associated neurogenic-inflammatory/vascular changes. The American Headache Society's evidence assessment already rates aspirin as Level A (well-established) for acute migraine treatment in general, and smaller retrospective and observational studies specifically in migraine-with-aura populations (e.g., a 203-patient retrospective cohort and a dedicated observational case series) suggest a possible prophylactic benefit. Because aspirin is not a vasoconstrictor — unlike triptans — it does not carry the same theoretical contraindication concerns that limit triptan use in brainstem aura.

That said, essentially all of the supporting literature addresses migraine or migraine-with-aura as a whole; no trial or publication in this pack specifically enrolled or confirmed patients with brainstem aura. The rationale is therefore a reasonable mechanistic extrapolation from the broader migraine-with-aura literature, not direct evidence for this specific, rare subtype — consistent with the L3 (observational/no RCT) evidence level assigned.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10448545	1999	RCT	Cephalalgia	Double-blind, double-dummy, multicenter RCT (n=278): IV lysine acetylsalicylate (≈1g ASA) vs. SC sumatriptan vs. placebo in acute migraine attacks (with or without aura)
26908949	2016	RCT	European Heart Journal	PRIMA trial: randomized evaluation of percutaneous PFO closure in migraine-with-aura patients refractory to medical treatment
25729594	2014	Retrospective Cohort	Current Health Sciences Journal	Retrospective review of 203 migraine-with-aura patients; 46.8% treated with low-dose ASA prophylaxis vs. other standard preventive therapies
29017164	2017	Observational Case Series	European Neurology	Aspirin used specifically as prophylaxis in patients with migraine with aura
39989443	2025	Systematic Review	Headache	Systematic review of antithrombotic drugs, including aspirin, as migraine preventive medication
25600718	2015	Guideline (AHS Evidence Assessment)	Headache	American Headache Society assessment classifies aspirin as Level A evidence for acute migraine pharmacotherapy
30291554	2018	Review	Current Pain and Headache Reports	Reviews pathophysiologic and clinical differences between episodic migraine with and without aura
34384631	2021	Review	Revue Neurologique	Describes cortical spreading depression as the pivotal mechanism underlying migraine aura
11139754	2000	Review	Revue Neurologique	Reviews prophylactic treatment strategies and indications for preventive therapy in migraine
16103551	2005	Case Report	Heart (British Cardiac Society)	Clopidogrel (an antiplatelet agent) reduced migraine-with-aura recurrence after transcatheter PFO/ASD closure

Norway Market Information

No marketing authorization records are currently on file for acetylsalicylic acid in Norway (0 licenses; market status "未上市/Not Marketed" in this dataset). Given that aspirin is a globally available generic, this likely reflects a gap in the specific regulatory data source rather than confirmed true market absence — this should be verified directly before any go/no-go decision.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

Aspirin has a mechanistically plausible role in migraine with aura — supported by one RCT (IV ASA vs. sumatriptan vs. placebo), a retrospective cohort, and an observational case series specifically studying aspirin in migraine-with-aura patients, plus a Level A general-migraine rating from the American Headache Society. However, no evidence in this pack directly addresses the brainstem-aura subtype, and overall evidence strength is L3 (observational, no dedicated RCT for this indication).

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/regulatory package insert warnings and contraindications — currently a complete data gap that blocks entry into the S1 safety pre-screening stage
Resolve DG002 (High): obtain detailed mechanism-of-action data via the DrugBank API to strengthen the mechanistic-relevance analysis
Confirm Norway marketing/regulatory status, since 0 authorizations are on record despite aspirin's status as a widely marketed generic drug
Seek or commission a study specifically enrolling migraine-with-brainstem-aura patients, since current evidence is extrapolated from the broader migraine-with-aura population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.